The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A first-in-human phase 1 dose-escalation study of the oral HIF-2a inhibitor JMKX003948 in patients with renal cell carcinoma.
 
Xieqiao Yan
No Relationships to Disclose
 
Xinan Sheng
No Relationships to Disclose
 
Zhihong Chi
No Relationships to Disclose
 
Chuanliang Cui
No Relationships to Disclose
 
Lu Si
Honoraria - MSD; Novartis; Shanghai Junshi Biosciences; Shanghai Kezhou Pharmaceutical
 
Yan Kong
No Relationships to Disclose
 
Bin Lian
No Relationships to Disclose
 
Lili Mao
No Relationships to Disclose
 
Juan Li
No Relationships to Disclose
 
Huayan Xu
No Relationships to Disclose
 
Xiaowen Wu
No Relationships to Disclose
 
Huihui Xiang
Employment - Shanghai Jeyou Pharmaceutical Co., Ltd.
 
Lina Gu
Employment - Shanghai Jeyou Pharmaceutical Co., Ltd.
 
Lei Yang
Employment - Jeyou pharmaceutical Co., Ltd.
 
Jun Guo
Consulting or Advisory Role - Bayer; BeiGene; Binhui Biopharmaceutical Co., Ltd.; Jiangsu Hengrui Medicine; MSD; Novartis; Pfizer; Roche; Shanghai Junshi BioSciences; Shanghai KeChow Pharma. Inc.